Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

SELL
$65.71 - $74.53 $98,499 - $111,720
-1,499 Reduced 19.4%
6,228 $425,000
Q4 2022

Jan 26, 2023

BUY
$68.48 - $81.09 $371,640 - $440,075
5,427 Added 235.96%
7,727 $556,000
Q3 2022

Oct 31, 2022

BUY
$0.13 - $76.84 $299 - $176,732
2,300 New
2,300 $165,000
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $36,334 - $43,568
-591 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $107,260 - $125,040
-2,000 Reduced 77.19%
591 $37,000
Q3 2021

Oct 25, 2021

SELL
$59.17 - $69.31 $294,548 - $345,025
-4,978 Reduced 65.77%
2,591 $153,000
Q2 2021

Jul 26, 2021

SELL
$61.91 - $67.42 $356,106 - $387,799
-5,752 Reduced 43.18%
7,569 $1.65 Million
Q1 2021

Apr 27, 2021

SELL
$59.34 - $66.74 $25,041 - $28,164
-422 Reduced 3.07%
13,321 $2.81 Million
Q4 2020

Jan 26, 2021

SELL
$57.74 - $65.43 $775,448 - $878,724
-13,430 Reduced 49.42%
13,743 $2.68 Million
Q3 2020

Oct 20, 2020

BUY
$57.43 - $63.64 $1.26 Million - $1.39 Million
21,854 Added 410.87%
27,173 $1.64 Million
Q2 2020

Jul 14, 2020

SELL
$54.82 - $64.09 $43,307 - $50,631
-790 Reduced 12.93%
5,319 $313,000
Q1 2020

Apr 28, 2020

BUY
$46.4 - $67.43 $41,296 - $60,012
890 Added 17.05%
6,109 $341,000
Q4 2019

Jan 23, 2020

BUY
$49.21 - $64.19 $224,102 - $292,321
4,554 Added 684.81%
5,219 $335,000
Q3 2019

Nov 06, 2019

BUY
$42.77 - $50.71 $9,837 - $11,663
230 Added 52.87%
665 $34,000
Q2 2019

Jul 22, 2019

SELL
$44.62 - $49.34 $230,328 - $254,693
-5,162 Reduced 92.23%
435 $20,000
Q1 2019

Apr 18, 2019

BUY
$45.12 - $53.8 $117,176 - $139,718
2,597 Added 86.57%
5,597 $267,000
Q1 2018

Apr 30, 2018

BUY
$59.92 - $68.98 $179,760 - $206,940
3,000 New
3,000 $190,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Harel Insurance Investments & Financial Services Ltd. Portfolio

Follow Harel Insurance Investments & Financial Services Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.